Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Human Metabolome Technologies, Inc. ( (JP:6090) ).
Human Metabolome Technologies, Inc. reported an 8.1% increase in net sales and a 13.3% rise in operating profit for the fiscal year ending June 2025, indicating strong operational performance. Despite a slight decline in ordinary profit, the company maintained a high capital adequacy ratio of 79.6%, reflecting robust financial health and stability.
More about Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc. operates in the biotechnology industry, focusing on metabolome analysis and related services. The company is listed on the Tokyo Stock Exchange and specializes in providing comprehensive metabolomics solutions to various sectors, including healthcare and pharmaceuticals.
Average Trading Volume: 11,940
Technical Sentiment Signal: Buy
Current Market Cap: Yen4.61B
See more data about 6090 stock on TipRanks’ Stock Analysis page.